Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse physiological
functions. Its two isoforms (α and β) are widely expressed throughout the body in sensory …

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however,
many patients with migraine do not benefit from drugs that antagonize the CGRPergic …

Objective To incorporate recent research findings, expert consensus, and patient
perspectives into updated guidance on the use of new acute and preventive treatments for …

Introduction Combination use of onabotulinumtoxinA and calcitonin gene–related peptide
(CGRP) monoclonal antibodies (mAbs) has the potential to be more effective than either …

Chronic migraine is a neurologic disorder associated with considerable disability, lost
productivity, and a profound economic burden worldwide. The past five years have seen a …

Background Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its
receptor (anti-CGRP (-R) mAbs) and small-molecule CGRP receptor antagonists (gepants) …

PURPOSE OF REVIEW This article provides an overview of preventive interventions for
migraine, including when to start and how to choose a treatment, pharmacologic options …

The monoclonal antibodies (mAbs) blocking the calcitonin-gene related peptide (CGRP)
pathway, collectively called here “anti-CGRP/rec mAbs”, have dramatically improved …

Calcitonin gene-related peptide (CGRP), a 37 amino-acid neuropeptide found mostly in
peptidergic sensory C-fibers, has been suggested to be implicated in the pathogenesis of …

We sought to assess the effectiveness of combining dual therapy with onabotulinumtoxinA
(BTX) add-on to anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (anti …